Sponsor:
Cerenovus, Part of DePuy Synthes Products, Inc.
Code:
NCT06735833
Conditions
Migraine Disorders
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Interventions
Middle Meningeal Artery embolization
Brief summary:
Conditions
Migraine Disorders
Study ID
NCT06735833
Start date
Apr 23, 2025
Status verified date
Aug, 2026
Completion date
Jul 31, 2029
Anticipated
Primary completion date
Dec 25, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 65
Healthy Volunteers: Not accepted
Enrollment
70 participants
Anticipated
Intervention Model
Single group
Primary purpose
Device Feasibility
Interventions
Middle Meningeal Artery embolization
Primary outcome measure
Central contacts
Study Contact
RA-MIGRAINECNV202302@ITS.JNJ.comLocations
John Muir Physician Network Clin. Research Center
Recruiting
Walnut Creek, California, United States, 94598
Hartford Hospital
Recruiting
Hartford, Connecticut, United States, 06032
Mount Sinai
Recruiting
New York, New York, United States, 10029
Stony Brook University Medical Center
Recruiting
Stony Brook, New York, United States, 11794
Thomas Jefferson University Hospital
Recruiting
Philadelphia, Pennsylvania, United States, 19107
Semmes Murphey Foundation
Recruiting
Memphis, Tennessee, United States, 38120
West Virginia University
Recruiting
Morgantown, West Virginia, United States, 26506
Sponsor
Cerenovus, Part of DePuy Synthes Products, Inc.
Last update posted
Aug 28, 2026
Last verified
Aug, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-11. This information was provided to ClinicalTrials.gov by Cerenovus, Part of DePuy Synthes Products, Inc. on 2026-08-28.